Gastroenterology

Gastroenterology

Volume 125, Issue 4, October 2003, Pages 1219-1226
Gastroenterology

Clinical management
Dyspepsia1

https://doi.org/10.1016/j.gastro.2003.07.001Get rights and content

Section snippets

Clinical case

A 44-year-old man presents with a 1-year history of intermittent pain in the epigastric region, which often occurs one hour after meals. The pain does not radiate and he has no weight loss, vomiting, or symptoms of GI bleeding. He denies early satiety, bloating, constipation, or diarrhea. He reports heartburn about twice a month, typically when he goes to bed soon after eating a large meal. He is otherwise healthy, is not obese, and takes no medications.

Definitions

Dyspepsia is currently defined as discomfort or pain centered in the upper abdomen; there are often accompanying symptoms including fullness, bloating, or early satiety.1, 2 More recently, it has been proposed that weight loss is a specific dyspepsia symptom, suggesting that the current nosology may need revision.3 The exclusion of heartburn from dyspepsia continues to be debated.1, 2

Epidemiology and natural history

Our patient has uninvestigated dyspepsia, which is a very common complaint everywhere.4, 5, 6 In the United

Recommended initial management strategy

For our case (young patient with no alarm symptoms), I would apply a test-and-treat strategy unless I practiced in a region where H. pylori is uncommon (prevalence <20%); if the patient is H. pylori positive then I would prescribe triple therapy for 10 days as is standard in the USA (although 1 week may be sufficient).42, 48 I would re-test the patient for H. pylori infection to confirm eradication if symptoms recurred. The cost-effectiveness of testing everyone after therapy is likely to be

Evolution of the case

The patient is tested for H. pylori with a stool antigen test and the result is positive. He is treated with a 10-day course of twice-daily triple therapy. However, 6 weeks later, he reports his symptoms are unchanged. A urea breath test confirms eradication. A trial of PPI therapy given twice daily for 4 weeks leads to no more than a 10% improvement in symptoms. Upper endoscopy is then performed and is normal.

Re-evaluation

Here we have a problem because very limited second-line options are available for patients with documented functional dyspepsia. I would re-evaluate the data used to make the diagnosis. One could give even higher dose PPI therapy for another 2 to 4 weeks, or try and ensure atypical reflux disease has been excluded by 24-hour esophageal pH testing off therapy. Occasionally, an uncommon disease will masquerade as functional dyspepsia. Occult pancreatic adenocarcinoma can present this way although

Treatment options

I suggest that the next step in management after failing standard therapies is to consider a trial of an antidepressant or psychological therapy. There are very limited data that tricyclic antidepressants are efficacious in functional dyspepsia, and no adequate trials.57 No trials have tested the selective serotonin re-uptake inhibitors (SSRIs) although they may have a role in IBS.58 I would try to start off with a low-dose tricyclic initially (e.g., imipramine or desipramine 10 to 25 mg at

Conclusions

The patient who presents with dyspepsia needs an appropriate, evidence-based clinical evaluation. In patients with alarm features and in older patients with new symptoms, prompt EGD is considered the gold standard to ensure malignancy has not been missed and to plan further management. Patients under the age of 50 years with no alarm features should be tested for H. pylori with an appropriate nonendoscopic test (e.g., a stool antigen test or C13 or C14 urea breath test) and treated if positive

First page preview

First page preview
Click to open first page preview

References (62)

  • M. Samsom et al.

    Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients

    Gastroenterology

    (1999)
  • B.M.R. Spiegel et al.

    Dyspepsia management in primary carea reappraisal of competing strategies

    Gastroenterology

    (2002)
  • D. Gillen et al.

    Problems related to acid rebound and tachyphylaxis

    Best Pract Res Clin Gastroenterol

    (2001)
  • A.T. Lassen et al.

    Helicobacter pylori test-and-eradication versus prompt endoscopy for management of dyspepsia patientsa randomised trial

    Lancet

    (2000)
  • U. Ladabaum et al.

    Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States

    Am J Gastroenterol

    (2002)
  • P.H. Katelaris et al.

    A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradicationthe QUADRATE Study

    Gastroenterology

    (2002)
  • C. Quan et al.

    Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs

    Am J Gastroenterol

    (2002)
  • S.J. Veldhuyzen van Zanten et al.

    Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsiaa meta-analysis

    Am J Gastroenterol

    (2001)
  • D.J. Kearney et al.

    Treatment of uninvestigaged dyspepsia with cisapride for patients with negative Helicobacter pylori serologies

    Am J Gastroenterol

    (2000)
  • J.L. Jackson et al.

    Treatment of functional gastrointestinal disorders with antidepressant medicationsa meta-analysis

    Am J Med

    (2000)
  • F. Creed et al.

    The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome

    Gastroenterology

    (2003)
  • E.L. Calvert et al.

    Long-term improvement in functional dyspepsia using hypnotherapy

    Gastroenterology

    (2002)
  • D.A. Drossman et al.

    The functional gastrointestinal disorders

  • N.J. Talley et al.

    Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders

    Am J Epidemiol

    (1992)
  • L. Agréus et al.

    The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden

    Pharmacoeconomics

    (2002)
  • R. Johnsen et al.

    Prevalences of endoscopic and histological findings in subjects with and without dyspepsia

    BMJ

    (1991)
  • J. Hallas et al.

    Screening for drug related dyspepsiaan analysis of prescription symmetry

    Eur J Gastroenterol Hepatol

    (1998)
  • C.J. Hawkey et al.

    Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors

    Gut

    (2003)
  • J. Dent et al.

    Management of gastro-oesophageal reflux disease in general practice

    BMJ

    (2001)
  • R. Carlsson et al.

    The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease

    Scand J Gastroenterol

    (1998)
  • P. Bytzer et al.

    Dyspepsia

    Ann Intern Med

    (2001)
  • Cited by (0)

    1

    Loren Laine, M.D.

    Clinical Management Editor

    University of Southern California

    Los Angeles, California

    View full text